Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 3/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21324101 | 0.89 | EGLN1 (0.39) | MAPK14P4HTMALKBH1NR4A2 | |
| SCHEMBL1758499 | 0.79 | PKM (0.48) | MAPK14P4HTMALKBH1FOLH1MAP4K4 | |
| SCHEMBL21265240 | 0.76 | LRRK2 (0.46) | PTGER1MAPTTDP1L3MBTL1 | |
| SCHEMBL21248333 | 0.69 | ATR (0.48) | PTGER1MAPT | |
| SCHEMBL21248383 | 0.68 | CYP1A2 (0.44) | P4HTMALKBH1SRD5A2TDP1 | |
| SCHEMBL8204822 | 0.68 | FOLH1 (0.69) | FOLH1PTGER1SRD5A2EDNRAMAPT | |
| SCHEMBL12750503 | 0.67 | FOLH1 (0.42) | P4HTMALKBH1FOLH1MAP4K4NR4A2 | |
| SCHEMBL31539866 | 0.66 | EDNRA (0.49) | FOLH1PTGER1SRD5A2EDNRAMAPT | |
| SCHEMBL1758500 | 0.66 | MAPK14 (0.44) | MAPK14P4HTMALKBH1FOLH1MAP4K4 | |
| SCHEMBL22445356 | 0.66 | LIPE (0.48) | MAPK14P4HTMALKBH1MAP4K4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219495-A1 | AHR MODULATORS | Ideaya Biosciences, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230039955-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11407764-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210002297-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10815250-B2 | AhR modulators | IDEAYA BIOSCIENCES, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190270754-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
| WO-2019156987-A1 | AhR MODULATORS | IDEAYA BIOSCIENCES, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407764-B2 | AhR modulators | AHR, ARNT, RORB | MAPK14 3448/4885P4HTM 146/4885ALKBH1 942/4885 |
| US-20230039955-A1 | AhR MODULATORS | AHR, ARNT, RORB | MAPK14 3418/4885P4HTM 149/4885ALKBH1 957/4885 |
| US-10815250-B2 | AhR modulators | AHR, ARNT, RORB | MAPK14 3448/4885P4HTM 146/4885ALKBH1 942/4885 |
| US-20210002297-A1 | AhR MODULATORS | AHR, ARNT, RORB | MAPK14 3448/4885P4HTM 146/4885ALKBH1 942/4885 |
| US-20190270754-A1 | AhR MODULATORS | AHR, ARNT, RORB | MAPK14 3448/4885P4HTM 146/4885ALKBH1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.